Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT01070316
• Date of registration: 15/02/2010
• Prospective Registration: No
• Primary sponsor: Children's Hospital Medical Center, Cincinnati
• Public title: Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
• Scientific title: Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex
• Date of first enrolment: January 2010
• Target sample size: 20
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01070316
• Study type: Interventional
• Study design: Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

United States

Contacts

• Name: Darcy Krueger, M.D. Ph.D
• Affiliation: Children's Hospital Medical Center, Cincinnati

Key inclusion & exclusion criteria

Inclusion Criteria:

- Male or female individuals aged two years and older.

- History of epilepsy and at least eight reported seizures in previous 30 days prior to
informed consent

- Failure of two or more approved antiepileptic drug therapies

- Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria or
positive genetic test)

- Parents/Caregivers are English-speaking (primary or secondary language acceptable)

- If female and of child bearing potential, documentation of negative pregnancy test at
time of informed consent. Sexually active pre-menopausal female or male patients must
use adequate contraceptive measures, excluding use of estrogen-containing birth
control contraceptive regimen while on study medication. Prior hysterectomy, tubal
ligation, complete abstinence, barrier methods which include both a cervical diaphragm
and spermicidal jelly, intrauterine devices (IUD), progesterone based contraceptives,
or vasectomy in partner are all acceptable forms of contraception

- Adequate bone marrow function as shown by ANC = 1.5 x 109/L, Platelets = 100 x 109/L,
and Hb >9 g/dL

- Adequate liver function as shown by serum bilirubin = 1.5 x upper limit of normal
(ULN), ALT and AST = 2.5x ULN, INR and PTT =1.5. (Anticoagulation is allowed if target
INR = 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks
at time of randomization.)

- Adequate renal function as shown by a serum creatinine = 1.5 x ULN

- Fasting serum cholesterol =300 mg/dL OR =7.75 mmol/L AND fasting triglycerides = 2.5 x
ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only
be included after initiation of appropriate lipid lowering medication

Exclusion Criteria:

- Significant hematological or hepatic abnormality (i.e., transaminase levels > 2.5 x
ULN or serum bilirubin >1.5 x ULN, Hemoglobin < 9 g/dL, platelets < < 100 X 109/L ,
absolute neutrophil count < 1.5 x 109/L)

- Patients currently receiving anticancer therapies or who have received anticancer
therapies within 4 weeks of the start of study drug (including chemotherapy, radiation
therapy, antibody based therapy, etc.)

- Patients, who have had a major surgery or significant traumatic injury within 4 weeks
of start of study drug, patients who have not recovered from the side effects of any
major surgery (defined as requiring general anesthesia) or patients that may require
major surgery during the course of the study

- Prior treatment with any investigational drug within the preceding 4 weeks prior to
informed consent

- Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent. Topical or inhaled corticosteroids are allowed

- Patients should not receive immunization with attenuated live vaccines within one week
of informed consent or during study period

- Patients with coexisting malignancies within past 3 years, except for adequately
treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to
require glucocorticoids for brain or leptomeningeal metastases

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study such as:

- Symptomatic congestive heart failure of New York heart Association Class III or
IV, unstable angina pectoris, symptomatic congestive heart failure, myocardial
infarction within 6 months of start of study drug, serious uncontrolled cardiac
arrhythmia or any other clinically significant cardiac disease

- Severely impaired lung function defined as spirometry and DLCO that is 50% of the
normal predicted value and/or 02 saturation that is 88% or less at rest on room
air and/or requirement for continuous supplemental O2

- Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN

- Active (acute or chronic) or uncontrolled severe infections

- Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
hepatitis

- A known history of HIV seropositivity

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small
bowel resection)

- Patients with an active, bleeding diathesis

- Female patients who are pregnant or breast feeding, or adults of
reproductive potential who are not using effective birth control methods.

- Patients who have received prior treatment with an mTOR inhibitor
(sirolimus, temsirolimus, everolimus).

- Patients with a known hypersensitivity to RAD001 (everolimus) or other
rapamycin (sirolimus, temsirolimus) or to its excipients

- History of noncompliance to medical regimens



Age minimum: 2 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Epilepsy

Tuberous Sclerosis Complex

Intervention(s)

Drug: Everolimus

Primary Outcome(s)

Number of Participants Continuing Study Medication Over Time [Time Frame: Individual subjects will be assessed every 6 months for up to 48 months; aggregate analysis will take place at end of study]

Reduction in Seizure Frequency [Time Frame: Baseline (Weeks 1-4), Week 16]

Secondary ID(s)

2009-0998

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Novartis

Results

• Results available: Yes
• Date Posted: 23/09/2016
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01070316